A recent analysis by the Kaiser Family Foundation finds that Medicare recipients taking Revlimid for cancer could end up paying, on average, $11,538 out of pocket for the drug in 2016, even if the medicine is covered by their Medicare Part D plan. Carmine Galasso/MCT/Landov hide caption

toggle caption Carmine Galasso/MCT/Landov

Retired California school teacher Mikkel Lawrence sits with his cat, Max. Lawrence has hepatitis C and has struggled to afford the medicine he needs to treat it. April Dembosky/KQED hide caption

toggle caption April Dembosky/KQED

Austin, Indiana's needle exchange program is open for business this week, but health workers worry the program will be tough to quickly replicate in other counties. Darron Cummings/AP hide caption

toggle caption Darron Cummings/AP
Indiana Struggles To Control HIV Outbreak Linked To Injected Drug Use
  • Download
  • <iframe src="https://www.npr.org/player/embed/403474785/403474795" width="100%" height="290" frameborder="0" scrolling="no" title="NPR embedded audio player">
  • Transcript

Volunteer Patrick Pezzati searches yards in Turners Falls, Mass., for discarded heroin needles. Karen Brown/WFCR hide caption

toggle caption Karen Brown/WFCR
A Rural Police Chief Asks Citizens To Help Pick Up Used Syringes
  • Download
  • <iframe src="https://www.npr.org/player/embed/401722597/402856156" width="100%" height="290" frameborder="0" scrolling="no" title="NPR embedded audio player">
  • Transcript

Volunteers search for needles and other drug paraphernalia along Church Street in Austin, Ind., in April. The region has recorded 142 new HIV cases since December, according to the state, in an outbreak tied to injected-opioid use. Seth Herald/Nurphoto/Corbis hide caption

toggle caption Seth Herald/Nurphoto/Corbis
CDC Warns More HIV, Hepatitis C Outbreaks Likely Among Drug Users
  • Download
  • <iframe src="https://www.npr.org/player/embed/401968600/402035073" width="100%" height="290" frameborder="0" scrolling="no" title="NPR embedded audio player">
  • Transcript

The hepatitis C medication Sovaldi, from Gilead Sciences, costs $1,000 per pill. It's just one of the new medications introduced in the past year that can cure the disease within weeks or months. Courtesy of Gilead Sciences via AP hide caption

toggle caption Courtesy of Gilead Sciences via AP
Costly Hepatitis C Drugs Threaten To Bust Prison Budgets
  • Download
  • <iframe src="https://www.npr.org/player/embed/372721256/372837243" width="100%" height="290" frameborder="0" scrolling="no" title="NPR embedded audio player">
  • Transcript

The newly approved Harvoni tablets bring several advances to the fight against hepatitis C, but they also have a steep price tag, reported at $1,125 for a single dose. Gilead Sciences hide caption

toggle caption Gilead Sciences

Walter Bianco's liver is severely damaged by hepatitis C, but insurers had refused to pay for the medications that could cure him. Alexandra Olgin for NPR hide caption

toggle caption Alexandra Olgin for NPR

Walter Bianco's liver is severely damaged by hepatitis C, but insurers had refused to pay for the medications that could cure him. Alexandra Olgin for NPR hide caption

toggle caption Alexandra Olgin for NPR
Medicare Backs Down On Denying Treatment For Hepatitis Patient
  • Download
  • <iframe src="https://www.npr.org/player/embed/312828866/312978146" width="100%" height="290" frameborder="0" scrolling="no" title="NPR embedded audio player">
  • Transcript

Advocates demonstrate in favor of cheaper generic drugs to treat hepatitis C in New Delhi on March 21. The disease is common among people who are HIV positive. Saurabh Das/AP hide caption

toggle caption Saurabh Das/AP

A girl with hepatitis C holds a medical report while being treated at a hospital in Hefei, China, in 2011. China has one of the greatest burdens of hepatitis C, but it's still not clear whether a deal for lower prices for a new drug from Gilead Sciences will apply there. Barcroft Media/Landov hide caption

toggle caption Barcroft Media/Landov

Timothy Webb and other advocates protest the cost of HIV drugs manufactured by the pharmaceutical company Gilead outside an AIDS conference in Atlanta in March. Gilead is making a new hepatitis C drug, Sovaldi. John Amis/AP Images for AIDS Healthcare Foundation hide caption

toggle caption John Amis/AP Images for AIDS Healthcare Foundation
$1,000 Pill For Hepatitis C Spurs Debate Over Drug Prices
  • Download
  • <iframe src="https://www.npr.org/player/embed/256885858/258301793" width="100%" height="290" frameborder="0" scrolling="no" title="NPR embedded audio player">
  • Transcript

A colorized closeup of the hepatitis C virus. James Cavallini/Science Source hide caption

toggle caption James Cavallini/Science Source
FDA Expected To Approve New, Gentler Cure For Hepatitis C
  • Download
  • <iframe src="https://www.npr.org/player/embed/248934833/248935208" width="100%" height="290" frameborder="0" scrolling="no" title="NPR embedded audio player">
  • Transcript

Particles of the hepatitis C virus are imaged with an electron microscope. James Cavallini/Science Source hide caption

toggle caption James Cavallini/Science Source

Hepatitis C patient Nancy Turner shows Kathleen Coleman, a nurse practitioner, where a forearm rash, a side effect of her treatment, has healed. Turner is one of many patients with hepatitis C experimenting with new drugs to beat back the virus. Richard Knox/NPR hide caption

toggle caption Richard Knox/NPR
As Hepatitis C Sneaks Up On Baby Boomers, Treatment Options Grow
  • Download
  • <iframe src="https://www.npr.org/player/embed/167258972/169305315" width="100%" height="290" frameborder="0" scrolling="no" title="NPR embedded audio player">
  • Transcript